Fennec Pharmaceuticals Inc. (TSE:FRX) Director Acquires C$96,840.00 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov purchased 25,000 shares of Fennec Pharmaceuticals stock in a transaction on Friday, December 20th. The shares were acquired at an average cost of C$3.87 per share, for a total transaction of C$96,840.00.

Rostislav Christov Raykov also recently made the following trade(s):

• On Thursday, December 5th, Rostislav Christov Raykov bought 796 shares of Fennec Pharmaceuticals stock. The stock was acquired at an average cost of C$8.52 per share, for a total transaction of C$6,779.05.
• On Wednesday, October 2nd, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$6.67, for a total transaction of C$16,212.34.

Fennec Pharmaceuticals Stock Up -0.9 %

Fennec Pharmaceuticals stock traded up C$0.03 during midday trading on Monday, hitting C$8.49. 486 shares of the company were exchanged, compared to its average volume of 2,005. The company has a market cap of C$232.29 million, a PE ratio of 84.90 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$5.65 and a fifty-two week high of C$15.43. The company’s fifty day moving average price is C$7.12 and its 200-day moving average price is C$7.67. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17.

Analyst Ratings Changes

Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.